{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:00:00Z","timestamp":1793048400385,"version":"4.5.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.coi.2021.03.005","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T01:29:13Z","timestamp":1617326953000},"page":"57-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"special_numbering":"C","title":["Tryptophan metabolism in brain tumors \u2014 IDO and beyond"],"prefix":"10.1016","volume":"70","author":[{"given":"Michael","family":"Platten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirco","family":"Friedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek A","family":"Wainwright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7750-3082","authenticated-orcid":false,"given":"Verena","family":"Panitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5575-9821","authenticated-orcid":false,"given":"Christiane A","family":"Opitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2021.03.005_sbref0005","article-title":"Metabolomic adaptations and correlates of survival to immune checkpoint blockade","volume":"10","author":"Li","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2021.03.005_sbref0010","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.cell.2020.07.038","article-title":"IL4I1 is a metabolic immune checkpoint that activates the AHR and promotes tumor progression","volume":"182","author":"Sadik","year":"2020","journal-title":"Cell"},{"issue":"Suppl. 3","key":"10.1016\/j.coi.2021.03.005_bib0015","first-page":"A423","article-title":"705 anti-tumor activity of CB-668, a potent, selective and orally bioavailable small-molecule inhibitor of the immuno-suppressive enzyme Interleukin 4 (IL-4)-Induced Gene 1 (IL4I1)","volume":"8","author":"MacKinnon","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.coi.2021.03.005_bib0020","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1240858","article-title":"The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas","volume":"5","author":"Sonner","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.coi.2021.03.005_bib0025","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.celrep.2016.10.079","article-title":"Stress kinase GCN2 controls the proliferative fitness and trafficking of cytotoxic T cells independent of environmental amino acid sensing","volume":"17","author":"Van de Velde","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.coi.2021.03.005_sbref0030","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nature10491","article-title":"An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor","volume":"478","author":"Opitz","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.coi.2021.03.005_bib0035","article-title":"Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-gamma-induced immunologic dormancy of tumor-repopulating cells","volume":"8","author":"Liu","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2021.03.005_bib0040","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ccell.2018.02.005","article-title":"Tumor-repopulating cells induce PD-1 expression in CD8(+) T cells by transferring kynurenine and AhR activation","volume":"33","author":"Liu","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.coi.2021.03.005_sbref0045","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41593-019-0370-y","article-title":"Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39","volume":"22","author":"Takenaka","year":"2019","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.coi.2021.03.005_sbref0050","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17750-z","article-title":"Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine","volume":"11","author":"Campesato","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2021.03.005_bib0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087877","article-title":"Identification of cinnabarinic acid as a novel endogenous aryl hydrocarbon receptor ligand that drives IL-22 production","volume":"9","author":"Lowe","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2021.03.005_bib0060","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00281-018-0702-0","article-title":"Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond","volume":"41","author":"Muller","year":"2019","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.coi.2021.03.005_bib0065","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coi.2021.03.005_sbref0070","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41568-019-0224-7","article-title":"Brain immunology and immunotherapy in brain tumours","volume":"20","author":"Sampson","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.coi.2021.03.005_bib0075","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1111\/j.1471-4159.1991.tb03460.x","article-title":"Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism","volume":"56","author":"Fukui","year":"1991","journal-title":"J Neurochem"},{"key":"10.1016\/j.coi.2021.03.005_sbref0080","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","article-title":"Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond","volume":"18","author":"Platten","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.coi.2021.03.005_bib0085","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf9794","article-title":"Kynurenines: Tryptophan\u2019s metabolites in exercise, inflammation, and mental health","volume":"357","author":"Cervenka","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.coi.2021.03.005_bib0090","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/978-1-4684-5952-4_95","article-title":"Production of quinolinic acid and kynurenic acid by human glioma","volume":"294","author":"Vezzani","year":"1991","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.coi.2021.03.005_bib0095","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1158\/0008-5472.CAN-12-3831","article-title":"The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress","volume":"73","author":"Sahm","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.coi.2021.03.005_bib0100","first-page":"485","article-title":"Hippocampal kynurenines as etiological factors in seizure disorders","volume":"39","author":"Schwarcz","year":"1987","journal-title":"Pol J Pharmacol Pharm"},{"key":"10.1016\/j.coi.2021.03.005_bib0105","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0304-3940(84)90050-8","article-title":"Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid","volume":"48","author":"Foster","year":"1984","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.coi.2021.03.005_bib0110","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s00109-013-1075-4","article-title":"The ACMSD gene, involved in tryptophan metabolism, is mutated in a family with cortical myoclonus, epilepsy, and parkinsonism","volume":"91","author":"Marti-Masso","year":"2013","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.coi.2021.03.005_bib0115","article-title":"Ketogenic diets for drug-resistant epilepsy","volume":"6","author":"Martin-McGill","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.coi.2021.03.005_bib0120","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.seizure.2019.05.006","article-title":"Changes in tryptophan and kynurenine pathway metabolites in the blood of children treated with ketogenic diet for refractory epilepsy","volume":"69","author":"Zarnowska","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.coi.2021.03.005_bib0125","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1111\/bph.14491","article-title":"Effects of levetiracetam on astroglial release of kynurenine-pathway metabolites","volume":"175","author":"Fukuyama","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.coi.2021.03.005_bib0130","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cobeha.2019.01.009","article-title":"The interplay among psychological distress, the immune system, and brain tumor patient outcomes","volume":"28","author":"Otto-Meyer","year":"2019","journal-title":"Curr Opin Behav Sci"},{"key":"10.1016\/j.coi.2021.03.005_bib0135","article-title":"The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies","author":"Marx","year":"2020","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.coi.2021.03.005_bib0140","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41380-019-0414-4","article-title":"The kynurenine pathway: a finger in every pie","volume":"25","author":"Savitz","year":"2020","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.coi.2021.03.005_bib0145","article-title":"Depression and tryptophan metabolism in patients with primary brain tumors: clinical and molecular imaging correlates","author":"John","year":"2020","journal-title":"Brain Imaging Behav"},{"key":"10.1016\/j.coi.2021.03.005_bib0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2020.11.008","article-title":"The double life of serotonin metabolites: in the mood for joining neuronal and immune systems","volume":"70","author":"Mondanelli","year":"2020","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coi.2021.03.005_sbref0155","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1073\/pnas.1918215117","article-title":"Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation","volume":"117","author":"Mondanelli","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2021.03.005_bib0160","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/neuonc\/nox210","article-title":"Monoamines in glioblastoma: complex biology with therapeutic potential","volume":"20","author":"Caragher","year":"2018","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.coi.2021.03.005_bib0165","article-title":"A retrospective survival analysis of Glioblastoma patients treated with selective serotonin reuptake inhibitors","volume":"2","author":"Otto-Meyer","year":"2020","journal-title":"Brain Behav Immun Health"},{"key":"10.1016\/j.coi.2021.03.005_bib0170","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3389\/fimmu.2020.00120","article-title":"Macrophages\/microglia represent the major source of indolamine 2,3-dioxygenase expression in melanoma metastases of the brain","volume":"11","author":"Herrera-Rios","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2021.03.005_bib0175","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nm.2092","article-title":"Kynurenine is an endothelium-derived relaxing factor produced during inflammation","volume":"16","author":"Wang","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2021.03.005_sbref0180","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1158\/1078-0432.CCR-19-3874","article-title":"Advanced age increases immunosuppression in the brain and decreases immunotherapeutic efficacy in subjects with glioblastoma","volume":"26","author":"Ladomersky","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coi.2021.03.005_bib0185","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1158\/1078-0432.CCR-17-3573","article-title":"IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma","volume":"24","author":"Ladomersky","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coi.2021.03.005_bib0190","article-title":"Trial watch: IDO inhibitors in cancer therapy","volume":"9","author":"Le Naour","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.coi.2021.03.005_bib0195","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1073\/pnas.1113873109","article-title":"Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase","volume":"109","author":"Pilotte","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2021.03.005_bib0200","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/jnc.13503","article-title":"Tryptophan-2,3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4","volume":"136","author":"Ochs","year":"2016","journal-title":"J Neurochem"},{"key":"10.1016\/j.coi.2021.03.005_bib0205","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3389\/fimmu.2020.00657","article-title":"Constitutive expression of the immunosuppressive tryptophan dioxygenase TDO2 in glioblastoma is driven by the transcription factor C\/EBPbeta","volume":"11","author":"Kudo","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2021.03.005_bib0210","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11060-018-2869-6","article-title":"Investigation of the aryl hydrocarbon receptor and the intrinsic tumoral component of the kynurenine pathway of tryptophan metabolism in primary brain tumors","volume":"139","author":"Guastella","year":"2018","journal-title":"J Neurooncol"},{"key":"10.1016\/j.coi.2021.03.005_bib0215","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11060-019-03198-9","article-title":"Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas","volume":"144","author":"Hao","year":"2019","journal-title":"J Neurooncol"},{"key":"10.1016\/j.coi.2021.03.005_bib0220","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/glia.22734","article-title":"Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway","volume":"63","author":"Ott","year":"2015","journal-title":"Glia"},{"key":"10.1016\/j.coi.2021.03.005_bib0225","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.3389\/fimmu.2019.02762","article-title":"Hypoxia inducible factor 1alpha inhibits the expression of immunosuppressive tryptophan-2,3-dioxygenase in glioblastoma","volume":"10","author":"Mohapatra","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2021.03.005_bib0230","doi-asserted-by":"crossref","first-page":"590532","DOI":"10.3389\/fimmu.2021.590532","volume":"12","author":"Mohapatra","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2021.03.005_sbref0235","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/2326-6066.CIR-19-0041","article-title":"Inhibition of tryptophan-dioxygenase activity increases the antitumor efficacy of immune checkpoint inhibitors","volume":"8","author":"Schramme","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.coi.2021.03.005_bib0240","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ejmech.2018.11.010","article-title":"Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase","volume":"162","author":"Winters","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.coi.2021.03.005_bib0245","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000870","article-title":"Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors","volume":"8","author":"Naing","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.coi.2021.03.005_bib0250","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/neuonc\/noy169","article-title":"Multimodal imaging-defined subregions in newly diagnosed glioblastoma: impact on overall survival","volume":"21","author":"John","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.coi.2021.03.005_bib0255","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11060-018-03013-x","article-title":"Imaging tryptophan uptake with positron emission tomography in glioblastoma patients treated with indoximod","volume":"141","author":"Lukas","year":"2019","journal-title":"J Neurooncol"},{"key":"10.1016\/j.coi.2021.03.005_bib0260","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.immuni.2005.03.013","article-title":"GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase","volume":"22","author":"Munn","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.coi.2021.03.005_bib0265","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00262-019-02441-6","article-title":"GCN2 is essential for CD8(+) T cell survival and function in murine models of malignant glioma","volume":"69","author":"Rashidi","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.coi.2021.03.005_bib0270","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1486353","article-title":"Upregulation of tryptophanyl-tRNA synthethase adapts human cancer cells to nutritional stress caused by tryptophan degradation","volume":"7","author":"Adam","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.coi.2021.03.005_sbref0275","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41586-020-03054-1","article-title":"Anti-tumour immunity induces aberrant peptide presentation in melanoma","volume":"590","author":"Bartok","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.coi.2021.03.005_bib0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112945","article-title":"Involvement of the kynurenine pathway in human glioma pathophysiology","volume":"9","author":"Adams","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2021.03.005_bib0285","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1158\/1541-7786.MCR-19-0669","article-title":"Targeting NAD(+) biosynthesis overcomes panobinostat and bortezomib-induced malignant glioma resistance","volume":"18","author":"Jane","year":"2020","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.coi.2021.03.005_bib0290","doi-asserted-by":"crossref","first-page":"29273","DOI":"10.1074\/jbc.M111.262139","article-title":"NADH oxidase activity of indoleamine 2,3-dioxygenase","volume":"286","author":"Rosell","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coi.2021.03.005_bib0295","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.immuni.2018.07.010","article-title":"The environmental sensor AHR protects from inflammatory damage by maintaining intestinal stem cell homeostasis and barrier integrity","volume":"49","author":"Metidji","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.coi.2021.03.005_bib0300","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1124\/pr.114.009001","article-title":"The aryl hydrocarbon receptor in barrier organ physiology, immunology, and toxicology","volume":"67","author":"Esser","year":"2015","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.coi.2021.03.005_bib0305","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.str.2017.05.008","article-title":"Structural basis for Aryl hydrocarbon receptor-mediated gene activation","volume":"25","author":"Schulte","year":"2017","journal-title":"Structure"},{"key":"10.1016\/j.coi.2021.03.005_sbref0310","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41416-019-0664-6","article-title":"The therapeutic potential of targeting tryptophan catabolism in cancer","volume":"122","author":"Opitz","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.coi.2021.03.005_bib0315","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.18632\/oncotarget.1637","article-title":"Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR","volume":"5","author":"Litzenburger","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.coi.2021.03.005_bib0320","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1038\/onc.2009.104","article-title":"Aryl hydrocarbon receptor inhibition downregulates the TGF-beta\/Smad pathway in human glioblastoma cells","volume":"28","author":"Gramatzki","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.coi.2021.03.005_sbref0325","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41577-019-0125-8","article-title":"The aryl hydrocarbon receptor: an environmental sensor integrating immune responses in health and disease","volume":"19","author":"Rothhammer","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coi.2021.03.005_bib0330","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1093\/toxsci\/kfx215","article-title":"TCDD, FICZ, and other high affinity AhR ligands dose-dependently determine the fate of CD4+ T cell differentiation","volume":"161","author":"Ehrlich","year":"2018","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.coi.2021.03.005_bib0335","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21217849","article-title":"From suppressor T cells to regulatory T cells: how the journey that began with the discovery of the toxic effects of TCDD led to better understanding of the role of AhR in immunoregulation","volume":"21","author":"Prasad Singh","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coi.2021.03.005_bib0340","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.immuni.2017.08.016","article-title":"Aryl hydrocarbon receptor controls monocyte differentiation into dendritic cells versus macrophages","volume":"47","author":"Goudot","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.coi.2021.03.005_bib0345","doi-asserted-by":"crossref","first-page":"12391","DOI":"10.1073\/pnas.1302856110","article-title":"Modulation of natural killer cell antitumor activity by the aryl hydrocarbon receptor","volume":"110","author":"Shin","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2021.03.005_bib0350","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/j.celrep.2019.10.018","article-title":"Aryl hydrocarbon receptor contributes to the transcriptional program of IL-10-producing regulatory B cells","volume":"29","author":"Piper","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.coi.2021.03.005_bib0355","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1084\/jem.20160789","article-title":"The aryl hydrocarbon receptor controls cell-fate decisions in B cells","volume":"214","author":"Vaidyanathan","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/j.coi.2021.03.005_bib0360","doi-asserted-by":"crossref","first-page":"116","DOI":"10.15252\/embj.201695027","article-title":"Aryl hydrocarbon receptor is required for optimal B-cell proliferation","volume":"36","author":"Villa","year":"2017","journal-title":"EMBO J"},{"key":"10.1016\/j.coi.2021.03.005_bib0365","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.coph.2020.07.001","article-title":"Targeting CD73 to augment cancer immunotherapy","volume":"53","author":"Roh","year":"2020","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.coi.2021.03.005_bib0370","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1158\/1541-7786.MCR-18-0362","article-title":"A role for tryptophan-2,3-dioxygenase in CD8 T-cell suppression and evidence of tryptophan catabolism in breast cancer patient plasma","volume":"17","author":"Greene","year":"2019","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.coi.2021.03.005_bib0375","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.4049\/jimmunol.0903670","article-title":"An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells","volume":"185","author":"Mezrich","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2021.03.005_bib0380","doi-asserted-by":"crossref","first-page":"20768","DOI":"10.1073\/pnas.1009201107","article-title":"An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis","volume":"107","author":"Quintana","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2021.03.005_bib0385","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/ni.1912","article-title":"The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27","volume":"11","author":"Apetoh","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coi.2021.03.005_bib0390","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/ni.1915","article-title":"Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells","volume":"11","author":"Gandhi","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coi.2021.03.005_bib0395","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.4049\/jimmunol.1300497","article-title":"The aryl hydrocarbon receptor promotes IL-10 production by NK cells","volume":"192","author":"Wagage","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2021.03.005_bib0400","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nature06880","article-title":"Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor","volume":"453","author":"Quintana","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.coi.2021.03.005_bib0405","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1007\/s10637-020-00950-1","article-title":"A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma","volume":"38","author":"Reardon","year":"2020","journal-title":"Invest New Drugs"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095279152100025X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095279152100025X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T08:41:33Z","timestamp":1760604093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095279152100025X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":81,"alternative-id":["S095279152100025X"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2021.03.005","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tryptophan metabolism in brain tumors \u2014 IDO and beyond","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2021.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}